TRD205

TRD205 is a first-in-class, highly selective small-molecule antagonist of the angiotensin II type 2 receptor (AT2R). Developed by Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharmaceutical Limited, it represents a novel non-opioid approach to the treatment of chronic neuropathic pain—including chronic post-surgical neuropathic pain (CPSP), inflammatory pain, and cancer pain. The drug works by precisely inhibiting AT2R activation in peripheral/cutaneous macrophages following nerve injury. This inhibition prevents the release of reactive oxygen/nitrogen species that would otherwise increase calcium influx in dorsal root ganglion sensory neurons and amplify pain sensitization. By targeting this pathway outside the central nervous system, TRD205 aims to suppress peripheral pain signaling without causing opioid-related side effects such as addiction or respiratory depression. It has demonstrated favorable safety and pharmacokinetic profiles in Phase I trials and is currently being evaluated in Phase II clinical studies for CPSP[1][3][5][6][7].